Zhou Yu-Chun, Huang Wei-Zhou, Shang Xue-Jun
Department of Andrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine,Jiangsu,Nanjing 210029,China.
Department of urology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine,Jiangsu,Nanjing 210029,China.
Zhonghua Nan Ke Xue. 2023 May;29(5):441-444.
To observe the clinical efficacy of Xiaoluowan (II) on epididymitis.
61 patients with epididymitis were divided into two groups, acute group (23 cases) and non-acute group (38 cases) . Both groups of patients were treated with Xiaoluowan (II) 6g twice a day orally, while acute group patients were given antibiotics intravenously. The treatment period is 4 weeks. The acute group evaluates the therapeutic efficacy comprehensively based on changes in clinical symptoms and signs, while recording changes in visual pain score (VAS). Chronic epididymitis symptom index (CESI) was used to evaluate the clinical symptoms before and after treatment in the non-acute group, and the curative efficacy was evaluated.
After treatment, the VAS scores in the acute group decreased from 7.08 ± 1.09 to 2.10 ± 1.37 (P<0.05). Total efficiency is 82.60% . In the non-acute group, the scores of pain before and after treatment were 7.08 ± 1.09 and 2.10 ± 1.37, the scores of quality of life were 7.28 ± 1.14 and 1.87 ± 1.56, the total scores were 14.37 ± 1.78 and 3.97±2.73, respectively. The difference was significant(P<0.05). Total efficiency is 84.21% .
Xiaoluowan (II) is an effective method to treat epididymitis and an effective supplement to modern medicine.
观察消络丸(II)治疗附睾炎的临床疗效。
将61例附睾炎患者分为两组,急性组(23例)和非急性组(38例)。两组患者均口服消络丸(II)6g,每日2次,急性组患者静脉滴注抗生素。疗程为4周。急性组根据临床症状和体征的变化综合评估治疗效果,同时记录视觉疼痛评分(VAS)的变化。非急性组采用慢性附睾炎症状指数(CESI)评估治疗前后的临床症状,并评价疗效。
治疗后,急性组VAS评分由7.08±1.09降至2.10±1.37(P<0.05)。总有效率为82.60%。非急性组治疗前后疼痛评分分别为7.08±1.09和2.10±1.37,生活质量评分分别为7.28±1.14和1.87±1.56,总分分别为14.37±1.78和3.97±2.73。差异有统计学意义(P<0.05)。总有效率为84.21%。
消络丸(II)是治疗附睾炎的有效方法,是现代医学的有效补充。